DAFNA Capital Management’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-140,847
| Closed | -$1.4M | – | 80 |
|
|
2025
Q2 | $1.4M | Sell |
140,847
-72,500
| -34% | -$584K | 0.39% | 47 |
|
|
2025
Q1 | $1.27M | Buy |
213,347
+25,000
| +13% | +$184K | 0.36% | 49 |
|
|
2024
Q4 | $1.45M | Buy |
188,347
+26,763
| +17% | +$230K | 0.37% | 47 |
|
|
2024
Q3 | $1.65M | Buy |
161,584
+17,224
| +12% | +$263K | 0.39% | 51 |
|
|
2024
Q2 | $2.14M | Buy |
144,360
+45,800
| +46% | +$656K | 0.51% | 42 |
|
|
2024
Q1 | $1.34M | Hold |
98,560
| – | – | 0.31% | 57 |
|
|
2023
Q4 | $1.08M | Hold |
98,560
| – | – | 0.26% | 60 |
|
|
2023
Q3 | $1.08M | Hold |
98,560
| – | – | 0.34% | 55 |
|
|
2023
Q2 | $1.3M | Hold |
98,560
| – | – | 0.36% | 48 |
|
|
2023
Q1 | $1.34M | Hold |
98,560
| – | – | 0.4% | 43 |
|
|
2022
Q4 | $1.92M | Buy |
98,560
+1,000
| +1% | +$19.5K | 0.54% | 47 |
|
|
2022
Q3 | $1.86M | Sell |
97,560
-7,738
| -7% | -$178K | 0.5% | 42 |
|
|
2022
Q2 | $2.17M | Buy |
105,298
+16,000
| +18% | +$380K | 0.59% | 43 |
|
|
2022
Q1 | $2.87M | Buy |
89,298
+35,208
| +65% | +$1.28M | 0.75% | 37 |
|
|
2021
Q4 | $2.52M | Sell |
54,090
-28,971
| -35% | -$964K | 0.63% | 36 |
|
|
2021
Q3 | $2.24M | Buy |
+83,061
| New | +$2.17M | 0.6% | 44 |
|
Other funds holding ITOS
DAFNA Capital Management's ITOS Position: Q3 2025 in Review
DAFNA Capital Management sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 140,847 shares — an estimated $1.4M sold.
DAFNA Capital Management first reported a position in ITOS in Q3 2021 and held it in 16 quarters. The position peaked at $2.87M in Q1 2022. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- DAFNA Capital Management reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- DAFNA Capital Management sold 140,847 iTeos Therapeutics shares in Q3 2025, an estimated $1.4M.
- DAFNA Capital Management first reported a position in iTeos Therapeutics in Q3 2021 and held it in 16 quarters.
- DAFNA Capital Management's iTeos Therapeutics position peaked at $2.87M in Q1 2022.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on DAFNA Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.